ISO 10993 biocompatibility before a Panama first-in-human device study: what the ethics committee reads, which endpoints, and when to bridge

Panama has no device-specific biocompatibility test list. The ethics committee reads your biological evaluation plan and report against ISO 10993-1. The endpoints for a permanent implant, where chemistry can replace animal tests, what large-animal work can carry, GLP and foreign studies under Article 102 of Executive Decree 21 of 2026, and when a manufacturing change forces a bridging rationale.

By Julio Martinez-Clark, CEO, bioaccess®

A sponsor planning a first-in-human device study in Panama usually asks two questions in the same email: what is 100% needed for GMP, and what is 100% needed for ISO 10993 biocompatibility, before the first patient. I have answered the GMP half separately (see GMP attestation or ISO 13485 certificate). This post is the biocompatibility half: what MINSA and the ethics committee actually read, how the endpoint list works for a permanent implant, what your animal work can and cannot cover, and when a change in manufacturing forces you back to the lab.

The short answer

Panama does not publish its own biocompatibility test list. The ethics committee reviews the biological safety case you put in the investigator’s brochure, judged against recognized standards: ISO 10993-1 and, if you are also building a U.S. file, FDA’s September 2023 guidance on the use of ISO 10993-1. What the committee reads is a biological evaluation plan and report, tied to your ISO 14971 risk file. Every endpoint relevant to your contact type and duration has to be addressed, by existing data, by a test, or by a written rationale. A pile of test reports without that evaluation is the most common reason a package comes back with questions.

The 2025 edition of ISO 10993-1 is now published. Check FDA’s recognized-consensus-standards database for the transition period if you need the same package to serve an IDE later.

The endpoint list is not a checklist

For a permanent tissue implant (contact longer than 30 days), the endpoints you must address under ISO 10993-1 and the FDA guidance are:

  • Cytotoxicity
  • Sensitization
  • Irritation or intracutaneous reactivity
  • Acute systemic toxicity
  • Material-mediated pyrogenicity
  • Subacute or subchronic toxicity
  • Genotoxicity
  • Implantation (local effects)
  • Chronic toxicity
  • Carcinogenicity

“Address” is the operative word. Hemocompatibility is not indicated if there is no circulating-blood contact, but say so for the implant and for each delivery-system component. A permanent, non-degrading material does not need the same degradation study a resorbable implant does; it does need evidence that the material does not meaningfully degrade in situ. Reproductive and developmental toxicity can often be closed by a written rationale based on constituents, likely exposure and the intended population.

The delivery system is a separate device-contact case. Short-term procedural tissue contact typically means cytotoxicity, sensitization, irritation, acute systemic toxicity and material-mediated pyrogenicity, each by test or by rationale. Sponsors forget this more often than you would expect.

Where chemistry can replace animals, and where it usually cannot

Chemical characterization under ISO 10993-18, plus a toxicological risk assessment under ISO 10993-17, can replace or reduce some animal tests when extractables from the final, sterilized device are identified and the toxicological margins are adequate. In practice that most often reduces systemic toxicity testing, and sometimes irritation.

For a novel, permanent implant, cytotoxicity, sensitization, genotoxicity and implantation are still usually tested rather than waived. Chronic toxicity and carcinogenicity may be addressed for a first-in-human study by a documented rationale if the risk assessment, genotoxicity and implant data support it. That is not automatic, and those endpoints come back for later marketing applications. Negative genotoxicity alone does not close the carcinogenicity question.

If the implant forms or cures in the body, the evaluation has to cover the product as delivered and the implant after it has formed, including residual or unreacted constituents present while it sets. Those starting materials belong in the chemical characterization.

What your large-animal work can carry

A clinically relevant large-animal study is often the strongest piece of the package, but only for the endpoints it was designed to read:

  • It can support the implantation / local effects endpoint if histopathology was collected so it can be read against ISO 10993-6.
  • A study of about 13 weeks can support subchronic and local effects. It is not, by itself, a chronic toxicity study.
  • Small animal numbers are common at this stage. They need a written justification, not silence.
  • A relevant in vivo model often reduces the need for a separate standard subcutaneous or muscle implantation study, although a short screening implant study is sometimes still added for a new material.
  • In vitro work and published data on the material platform support the toxicological risk assessment. They do not replace device-specific chemistry and testing of the sterilized clinical formulation.

GLP and studies done outside Panama

Article 102 of Executive Decree 21 of 2026 requires preclinical studies, when necessary, to follow Good Laboratory Practice. In October 2026 MINSA’s research regulation unit confirmed to us, in answer to a general question, that Article 102 applies to preclinical work performed in Panama. Studies already completed abroad do not have to be repeated locally. They go in the investigator’s brochure, are expected to meet recognized standards, and the ethics committee assesses them case by case. More detail is in our guide to animal and preclinical data for a Panama FIH.

My advice has not changed: GLP is still the safest route for any new in vivo biocompatibility or safety study, and it is what FDA will expect for the U.S. file. If a study you are relying on was non-GLP, put a gap analysis and a quality statement in the brochure rather than hoping nobody asks.

Test the device you will implant, and know when to bridge

The ISO 10993 evaluation should be performed on the final finished form, after sterilization. If you change the manufacturing site, the formulation or the sterilization method after those tests, you need a bridging rationale or repeat testing. This is where Panama timelines quietly slip: a sponsor moves fill-finish or sterilization to a contract facility six months before first patient, and the biocompatibility data no longer describe the lots that will ship.

Three questions I ask every sponsor before we commit to a first-patient date:

  1. Which ISO 10993 tests, if any, were run on the sterilized clinical formulation, and on the delivery system if it uses different materials?
  2. Will the clinical lots be terminally sterilized or aseptically filled, and by which method? (Ethylene oxide also brings ISO 10993-7 residual limits into the file.)
  3. Will the facility that fills, finishes, packs and sterilizes the clinical lots be the same one that made the test articles? If any constituent is animal-derived, flag that too.

The answers decide whether the remaining work is a few weeks of rationale writing or a new round of testing that has to be commissioned now.

Frequently asked questions

Does Panama have its own biocompatibility test list for device FIH studies?

No. The ethics committee reviews the biological evaluation in the investigator’s brochure against recognized standards, principally ISO 10993-1. Each endpoint for your contact type and duration must be addressed by data, test or rationale.

Can I skip chronic toxicity and carcinogenicity testing for a permanent implant FIH?

Sometimes, with a documented rationale supported by chemical characterization, a toxicological risk assessment, genotoxicity and implantation data. It is not automatic, and those endpoints are revisited for marketing applications.

Do preclinical studies done in the UK or the U.S. have to be repeated in Panama?

No. MINSA’s reading of Article 102 of Executive Decree 21 of 2026 is that it applies to preclinical work done in Panama. Foreign studies go in the investigator’s brochure and are judged by the ethics committee against recognized standards.

If I change my sterilization provider after testing, do I have to retest?

You need either a bridging rationale showing the change does not affect the biological safety of the final device, or repeat testing. Plan that decision before you change suppliers, not after.

Sources

  • ISO 10993-1, Biological evaluation of medical devices, Part 1: Evaluation and testing within a risk management process (2018 edition; 2025 edition published).
  • U.S. FDA, “Use of International Standard ISO 10993-1, Biological evaluation of medical devices, Part 1,” final guidance, September 2023.
  • ISO 10993-6 (implantation), ISO 10993-7 (ethylene oxide residuals), ISO 10993-17 (toxicological risk assessment), ISO 10993-18 (chemical characterization); ISO 14971 (risk management).
  • Republic of Panama, Executive Decree 21 of 2026 (research regulation), Article 102; MINSA research regulation unit response to bioaccess®, October 2026.

If you are planning a first-in-human device study in Panama and want the biocompatibility and GMP files reviewed before the ethics-committee submission, talk to us about first-in-human trial execution in Latin America, or see our LATAM market access service. — bioaccess®

← Back to Blog · Contact bioaccess®